CAJ | 학술논문

目的：评价XELOX方案新辅助化疗治疗Ⅲ期进展期胃癌的近期疗效及安全性。方法采用单组、开放、非随机方法选择2010年7月至2012年6月47例经影像学检查证实的ⅢA、ⅢB、ⅢC进展期胃癌患者，采用XELOX方案化疗2～3个疗程后评价临床疗效，评估可否手术治疗。结果14例化疗2疗程后手术，23例化疗3疗程后手术，10例病情进展更换化疗方案，其中行根治性切除术29例，总有效率55.32%。临床受益率为78.72%。不同病理类型胃癌（高、中分化腺癌对比低分化腺癌及印戒细胞癌）对化疗的临床受益率，差异无显著性意义（P＞0.05）。化疗过程中最常见的毒副作用为白细胞降低及恶心、呕吐、腹泻、手足综合征。结论 XELOX方案新辅助化疗Ⅲ期进展期胃癌，毒副作用较小，能提高部分患者手术治疗疗效。
목적：평개XELOX방안신보조화료치료Ⅲ기진전기위암적근기료효급안전성。방법채용단조、개방、비수궤방법선택2010년7월지2012년6월47례경영상학검사증실적ⅢA、ⅢB、ⅢC진전기위암환자，채용XELOX방안화료2～3개료정후평개림상료효，평고가부수술치료。결과14례화료2료정후수술，23례화료3료정후수술，10례병정진전경환화료방안，기중행근치성절제술29례，총유효솔55.32%。림상수익솔위78.72%。불동병리류형위암（고、중분화선암대비저분화선암급인계세포암）대화료적림상수익솔，차이무현저성의의（P＞0.05）。화료과정중최상견적독부작용위백세포강저급악심、구토、복사、수족종합정。결론 XELOX방안신보조화료Ⅲ기진전기위암，독부작용교소，능제고부분환자수술치료료효。
Objective To evaluate the short-term effects and the safety of neoadjuvant chemotherapy with XELOX in stage Ⅲ advanced gastric cancer. Methods Using a single set, open, nonrandom method to select 47 patients in stage ⅢA,ⅢB and ⅢC advanced gastric cancer confirmed by imaging examinations during July 2010 to June 2012. To evaluate the patients could be treatment by surgical after received 2-3 period of neoadjuvant chemotherapy with XELOX. Results 14 patients received surgery treatment after 2 period of chemotherapy, 23 patients received surgery treatment after 3 period of chemotherapy. 10 patients were replaced chemotherapy regimens after progress disease. 29 patients received curative resection. The overall response rate was 55.32%and the positive rate of clinical benefit response was 78.72%. The clinical benefit response of chemotherapy had no statistical difference between different pathological type of gastric cancer(high-differentiated and middle-differentiated gastric cancer vs. poor-differentiated gastric cancer and signet ring cell gastric cancer)(P>0.05). The main side effects included leucopenia, nausea and vomiting, diarrhoea and hand-foot syndrome. Conclusion Neoadjuvant chemotherapy with XELOX in stage Ⅲ advanced gastric cancer have a less side effects and can improve the surgical curative effect of some patients.